Physician profile
Jonathan M Bernstein
NPI 1497750574
$7,608.99
in general payments reported to CMS, 2019-2025
15 companies · $28.95 in 2025
The $28.95 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,232 · 2020: $2,549 · 2021: $146 · 2022: $199 · 2023: $264 · 2024: $191 · 2025: $28.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.19 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $6,418.84 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $200.29 | 2019-2024 | Eylea, Eylea Hd |
| Biocryst US Sales Co., LLC | $171.26 | 2021-2022 | |
| Abbvie INC. | $150.10 | 2022-2023 | Durysta, Alphagan P, Lumigan |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Genentech USA, INC. | $135.93 | 2019-2022 | |
| Alimera Sciences, INC. | $119.83 | 2019 | |
| Allergan, INC. | $74.77 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $49.22 | 2022-2023 | Acthar |
| Optos, INC. | $35.72 | 2019 | |
| Leo Pharma INC. | $28.95 | 2025 | Anzupgo |
| Biotissue Holdings INC. | $24.44 | 2022 | |
| Amgen INC. | $22.45 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $15.49 | 2020 | |
| Alcon Vision LLC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.